Forma Therapeutics Holdings Inc

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers.

Our lead core product candidate, etavopivat, is an investigational agent that is designed to be a once-daily pill for the treatment of sickle cell disease. Etavopivat is a potent activator of pyruvate kinase-R (PKR), which is hypothesized to impact two pathways in the red blood cell. Another core investigational agent, FT-7051, is a potent and selective inhibitor of CBP/p300 in development for the treatment of metastatic prostate cancer that is resistant to standard-of-care regimens (mCRPC). We have exclusively licensed olutasidenib, an investigational agent, to Rigel Pharmaceuticals to develop, manufacture and commercialize for any uses worldwide, including for the treatment of R/R AML. Olutasidenib is an investigational agent designed to selectively inhibit mutated IDH1. In addition to our program in AML, we’re investigating olutasidenib in a Phase 1 clinical study for the treatment of gliomas due to favorable blood-brain barrier penetration and the high prevalence of mIDH1 in this indication.